BRIEF—Taiho Oncology broadens Lonsurf label

US-based Taiho Oncology has won US approval for Lonsurf (trifluridine/tipiracil) as a third-line treatment for adults with metastatic gastric or gastroesophageal junction adenocarcinoma.

Chief executive Timothy Whitten said: "The approval of Lonsurf represents a significant milestone for patients living with advanced gastric or GEJ adenocarcinoma who have limited effective treatment options after standard treatment options have failed."

The therapy is currently approved in the USA for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with standard chemotherapy.